Education
About Us
Working with TipRanks
Follow Us
Aurinia Pharmaceuticals (AUPH)
:AUPH
AUPH Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.29 - $11.80
Previous CloseN/A
Volume460.34K
Average Volume (3M)2.44M
Market Cap
$1.54B
Enterprise Value$931.54M
Total Cash (Recent Filing)$315.13M
Total Debt (Recent Filing)$81.83M
Price to Earnings (P/E)27.2
Beta0.79
Next Earnings
Oct 30, 2025EPS Estimate
0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.16
Shares Outstanding131,629,550
10 Day Avg. Volume3,097,642
30 Day Avg. Volume2,441,963
Financial Highlights & Ratios
PEG Ratio-2.08
Price to Book (P/B)3.40
Price to Sales (P/S)5.46
P/FCF Ratio29.13
Enterprise Value/Market Cap0.60
Enterprise Value/Revenue3.58
Enterprise Value/Gross Profit4.00
Enterprise Value/Ebitda10.77
Forecast
1Y Price Target
$12.00Price Target Upside2.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Financial PerformanceAurinia Pharmaceuticals reported strong 2Q25 financial results with total revenue exceeding consensus estimates, indicating robust company performance.
Market ConfidenceAurinia announced a new $150M share repurchase plan, demonstrating management's confidence in the company's long-term value.
Product SalesThe increase in Lupkynis net sales is attributed to factors such as increased rheumatologist adoption and expansion in the hospital channel.
Bears Say
Market StructureThere is disappointment that Aurinia will remain standalone, as more value could have been created with strategic synergies in a more established commercial organization.
Aurinia Pharmaceuticals News
AUPH FAQ
What was Aurinia Pharmaceuticals’s price range in the past 12 months?
Aurinia Pharmaceuticals lowest stock price was $5.29 and its highest was $11.80 in the past 12 months.
What is Aurinia Pharmaceuticals’s market cap?
Aurinia Pharmaceuticals’s market cap is $1.54B.
When is Aurinia Pharmaceuticals’s upcoming earnings report date?
Aurinia Pharmaceuticals’s upcoming earnings report date is Oct 30, 2025 which is in 84 days.
How were Aurinia Pharmaceuticals’s earnings last quarter?
Aurinia Pharmaceuticals released its earnings results on Jul 31, 2025. The company reported $0.16 earnings per share for the quarter, beating the consensus estimate of $0.147 by $0.013.
Is Aurinia Pharmaceuticals overvalued?
According to Wall Street analysts Aurinia Pharmaceuticals’s price is currently Undervalued.
Does Aurinia Pharmaceuticals pay dividends?
Aurinia Pharmaceuticals does not currently pay dividends.
What is Aurinia Pharmaceuticals’s EPS estimate?
Aurinia Pharmaceuticals’s EPS estimate is 0.16.
How many shares outstanding does Aurinia Pharmaceuticals have?
Aurinia Pharmaceuticals has 131,629,550 shares outstanding.
What happened to Aurinia Pharmaceuticals’s price movement after its last earnings report?
Aurinia Pharmaceuticals reported an EPS of $0.16 in its last earnings report, beating expectations of $0.147. Following the earnings report the stock price went up 2.099%.
Which hedge fund is a major shareholder of Aurinia Pharmaceuticals?
Currently, no hedge funds are holding shares in AUPH
Aurinia Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.00 (2.56% Upside)
$12.00 (2.56% Upside)
Blogger Sentiment
Bullish
AUPH Sentiment 70%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 13.6%
Last 30 Days ▲ 34.3%
Last 30 Days ▲ 34.3%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
106.58%
12-Months-Change
Fundamentals
Return on Equity
17.33%
Trailing 12-Months
Asset Growth
-4.00%
Trailing 12-Months
Company Description
Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
AUPH Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call indicates strong financial performance with significant revenue growth, improved cash flow, and positive clinical trial results, which have led to increased guidance. However, there are some concerns related to decreased cash reserves and restructuring costs. The highlights significantly outweigh the lowlights, suggesting a positive outlook.View all AUPH earnings summariesAUPH Revenue Breakdown
90.00% U.S.
10.00% Japan
AUPH Stock 12 Month Forecast
Average Price Target
$12.00
▲(2.56% Upside)
Technical Analysis
Celldex
―
Iovance Biotherapeutics
―
Ardelyx
―
Ocular Therapeutix
―
Liquidia Technologies
―
Ownership Overview
10.63% Insiders
5.63% Mutual Funds
0.13% Other Institutional Investors
77.16% Public Companies and
Individual Investors